What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
July 13 | Weekly Gain | My Watchlist |
|---|---|---|---|
|
Amerigroup |
$89.95 | 40% | Add |
|
Affymax |
$16.49 | 30% | Add |
|
Orexigen Therapeutics |
$7.06 | 22% | Add |
|
Complete Genomics |
$2.44 | 18% | Add |
|
SkyWest |
$7.96 | 14% | Add |
Source: Barron's.
Amerigroup was the picture of health, soaring nearly 40% after WellPoint struck a deal to acquire the Medicaid coverage specialist. The all-cash deal will take Amerigroup shareholders out at $92, a healthy premium to where the stock was just before the deal was announced.
Affymax was one of the market's biggest winners after a company announced that it would be rolling out Affymax's anemia drug Omontys -- a drug that boosts red blood cell production for dialysis patients -- in at least 100 dialysis centers.
Orexigen shares fattened up after the company reported strong enrollment for its diet-drug study. The heavy demand now finds Orexigen targeting interim analysis of the study concluding by early next year, a lot earlier than original expectations.
Complete Genomics was DNA -- as in Deserving Notable Appreciation -- after introducing a new technology that can potentially set the new standard for clinical-grade genomes.
Regional air carrier SkyWest took off after placing an order with Mitsubishi for 100 jets.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
